Practical Considerations and Implementation of Automated Insulin Delivery Systems
Diabetes Technology & Therapeutics · 2025-07 · 27 (3_suppl)
DOI: 10.1089/dia.2025.0132 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 01.07.2025. Verfasst von Laurel H Messer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Hauptthemen laut MEDLINE: Insulin Infusion Systems, Insulin, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Automated Insulin Delivery (AID) is in a new era of implementation challenges and opportunities for people with diabetes (PWD) and healthcare providers (HCPs). Beyond technologic variation, cost, access, and HCP endorsement/experience lead to uneven uptake of AID technologies, and attenuate universal ease of use. For AID to be broadly implemented, we must prioritize the lived experience for PWD, and consider how to alleviate burden to promote holistic wellbeing. Expectations and education help HCPs and PWD navigate the similarities and differences between AID devices, and help find common ties: users need to give the system time to work, learn to trust it, and not try to “trick” the system. Despite these learnings, disparities in uptake exist, both in clinical trials and in routine clinical care. Strategies to proactively address AID disparities are needed at multiple levels, all of which increase in importance as AID becomes more common for people with type 2 diabetes. Further, broader implementation will require comprehensive healthcare system integration efforts, including new data solutions. Overall, the success of AID requires ongoing transformation of clinical paradigms, with lockstep alignment between PWD and their families, healthcare professionals, researchers, funders, policy makers, and industry partners.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Tandem Diabetes Care, San Deigo, California, USA.
- Center for Diabetes Technology, University of Virginia, USA.
- Division of Endocrinology, Department of Pediatrics, Stanford University, Stanford, California, USA.
- T1D Exchange, Boston, Massachusetts, USA.
- Southern Health NHS Foundation Trust, Southampton, UK.
ORCID-Profile: Laurel H Messer, Gregory P Forlenza, Korey Hood, Osagie Ebekozien, Katharine Barnard-Kelly, Lori M Laffel, Jennifer L Sherr, Rayhan Lal, Stuart A Weinzimer
Förderung
- NIDDK NIH HHS
Zitieren
APA
Messer, L. H., Forlenza, G. P., Gonder-Frederick, L., Hood, K., Ebekozien, O., Barnard-Kelly, K., Laffel, L. M., Sherr, J. L., Lal, R., & Weinzimer, S. A. (2025). Practical Considerations and Implementation of Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics, 27(3_suppl). https://doi.org/10.1089/dia.2025.0132
Vancouver
Messer LH, Forlenza GP, Gonder-Frederick L, Hood K, Ebekozien O, Barnard-Kelly K, et al. Practical Considerations and Implementation of Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics. 2025;27(3_suppl). doi:10.1089/dia.2025.0132
BibTeX
@article{Messer2025,
author = {Messer, Laurel H and Forlenza, Gregory P and Gonder-Frederick, Linda and Hood, Korey and Ebekozien, Osagie and Barnard-Kelly, Katharine and Laffel, Lori M and Sherr, Jennifer L and Lal, Rayhan and Weinzimer, Stuart A},
title = {Practical Considerations and Implementation of Automated Insulin Delivery Systems},
journal = {Diabetes Technology & Therapeutics},
year = {2025},
volume = {27},
number = {3_suppl},
doi = {10.1089/dia.2025.0132}
}
EUVIMED